Trial reportEuropean journal of heart failure2022
A pilot clinical trial of cell therapy in heart failure with preserved ejection fraction.
Trial report in European journal of heart failure, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02923609 (A PILOT TRIAL OF CELL THERAPY IN HEART FAILURE WITH PRESERVED EJECTION FRACTION), which is not on this map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A pilot trial of cell therapy in heart failure with preserved ejection fraction
Who cites it
8 citing papers in PubMed, 10 citations in OpenAlex.
- TransEndocardial Injection of Autologous Expanded CD34Stem cell reviews and reports · 2026Trial
- Current concepts and challenges in pediatric diastolic dysfunction and heart failure with preserved ejection fraction.Pediatric research · 2026Review
- International Utah Cardiac Recovery Symposium (U-CARS) 2025: Clinical Science Proceedings.Heart failure reviews · 2026Article
- Designs of the clinical trials aiming at evaluating cell and gene therapy products: A critical appraisal from a literature review.Molecular therapy. Advances · 2026Review
- Targeted Overexpression of Mitochondrial ALDH2 in Coronary Endothelial Cells Mitigates HFpEF in a Diabetic Mouse Model.Biomolecules · 2025Article
- Focusing on microvascular function in heart failure with preserved ejection fraction.Heart failure reviews · 2025Review
- Breaking new ground in heart failure management: novel therapies and future frontiers.Frontiers in cardiovascular medicine · 2025Review
- New Opportunities in Heart Failure with Preserved Ejection Fraction: From Bench to Bedside… and Back.Biomedicines · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsWe investigated the effects of CD34 METHODS AND
resultsIn a prospective pilot study, we enrolled 30 patients with HFpEF. In Phase 1, patients were treated with medical therapy for 6 months. Thereafter, all patients underwent CD34
conclusionsIn this non-randomized trial, transendocardial CD34 CLINICAL
trial registrationClinicalTrials.gov NCT02923609.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.